- Joined
- 8 June 2014
- Posts
- 29
- Reactions
- 0
Fast becoming more women's health and less of IVF/ARS, although that is still it's core by quite some margin.
And I like this, as has been noted previously in this thread, ARS has proven to be a bit more cyclical/price-sensitive than many of us thought to be the case. By adding on additional revenues outside of the ARS sector, one would assume that the company is becoming less and less dependent on ARS. However, as you said, at it's core, its still an ARS company.